drugset / Trial / NCT02667483
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.
Timeline
- Start
- 2015-10
- Primary completion
- 2020-10-20
- Completion
- 2020-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DS-5141b | Unknown | 0.1 mg/kg | Subcutaneous |
| Subject | DS-5141b | Unknown | 0.5 mg/kg | Subcutaneous |
| Subject | DS-5141b | Unknown | 2 mg/kg | Subcutaneous |
| Subject | DS-5141b | Unknown | 6 mg/kg | Subcutaneous |